Insights into the disappointing clinical trials of antioxidants in neurodegenerative diseases

Journal of Alzheimer's Disease

Volumn 19, Issue 4, 2010, Pages 1141-1142

  Shen, Liang ^a   Ji, Hong Fang ^a  

^a SHANDONG UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; REACTIVE OXYGEN METABOLITE;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; CLINICAL TRIAL; DEGENERATIVE DISEASE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG METABOLISM; DRUG PENETRATION; HUMAN; HUNTINGTON CHOREA; LETTER; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL;

EID: 77950361072     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-1307     Document Type: Letter

References (14)

1. Kamat CD, Gadal S, Mhatre M, Williamson KS, Pye QN, Hensley K (2008) Antioxidants in central nervous system diseases: preclinical promise and translational challenges. J Alzheimers Dis 15, 473-493.
2. Steinhubl SR (2008) Why have antioxidants failed in clinical trials? Am J Cardiol 101, 14D-19D.
3. Lonn E, Bosch J, Yusuf S, Sheridan P, Pogue J, Arnold JM, Ross C, Arnold A, Sleight P, Probstfield J, Dagenais GR, HOPE and HOPE-TOO Trial Investigators (2005) Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA 293, 1338-1347.
4. Scalbert A,Williamson G (2000) Dietary intake and bioavailability of polyphenols. J Nutr 130, 2073S-2085S.
5. Vissers MN, Zock PL, Katan MB (2004) Bioavailability and antioxidant effects of olive oil phenols in humans: a review. Eur J Clin Nutr 58, 955-965.
6. Violi F, Micheletta F, Iuliano L (2001) Antioxidant strategy for cardiovascular disease. Lancet 357, 1704.
7. Shen L, Ji HF, Zhang HY (2007) How to understand the dichotomy of antioxidants? Biochem Biophys Res Commun 362, 543-545.
8. Zhang HY, Yang DP, Tang GY (2006) Multipotent antioxidants: from screening to design. Drug Discov Today 11, 749-754.
9. Ji HF, Zhang HY (2008) Multipotent natural agents to combat Alzheimer's disease. Functional spectrum and structural features. Acta Pharmacol Sin 29, 143-151.
10. Shen L, Ji HF (2007) Theoretical study on physicochemical properties of curcumin. Spectrochim Acta A Mol Biomol Spectrosc 67, 619-623.
11. Baum L, Ng A (2004) Curcumin interaction with copper and iron suggests one possible mechanism of action in Alzheimer's disease animal models. J Alzheimers Dis 6, 367-377.
12. Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambegaokar SS, Chen PP, Kayed R, Glabe CG, Frautschy SA, Cole GM. (2005) Curcumin inhibits formation of amyloid ? oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 280, 5892-5901.
13. Gafner S, Lee SK, Cuendet M, Barth́eĺemy S, Vergnes L, Labidalle S, Mehta RG, Boone CW, Pezzuto JM (2004) Biologic evaluation of curcumin and structural derivatives in cancer chemoprevention model systems. Phytochemistry 65, 2849-2859.
14. Shimmyo Y, Kihara T, Akaike A, Niidome T, Sugimoto H (2008) Epigallocatechin-3-gallate and curcumin suppress amyloid beta-induced beta-site APP cleaving enzyme-1 upregulation. Neuroreport 19, 1329-1333.